IDH2 and acute myeloid leukemia: Seven [14, 21–24, 26, 29] articles (7 cohorts) reported CR with IDH inhibitors in newly diagnosed IDH-mutated AML patients, and six [21–24, 26, 29] articles (6 cohorts) reported ORR with IDH inhibitors in newly diagnosed IDH-mutated AML patients.